Gilead Sciences Inc. closed 13.61% below its 52-week high of $119.96, which the company reached on March 10th.

At Gilead, putting people first is central to all we do. That’s why we’re proud to be recognized as a responsible company by patient advocacy groups representing more than 70 countries.

There’s a lot to be optimistic about in the Healthcare sector as 3 analysts just weighed in on Gilead Sciences (GILD – Research Report), Argenx ...